MIR:CC News and Press, Medmira Inc. From 06/06/22

HALIFAX, Nova Scotia, June 06, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of a U.S. patent (number 11,353,450) for their new innovative and quantitative test system. Through this new patent, MedMira is to further diversify its patent portfo...

HALIFAX, Nova Scotia, May 27, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on its regulatory progress in Europe and any market accepting the CE mark. MedMira has received the CE mark for three products in 2022 and has four additional applications cur...

HALIFAX, Nova Scotia, May 20, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on the Company’s regulatory work for Canada for its VYRA™ product line. On the 10 th of May 2022, Health Canada issued to all stakeholder further inform...

HALIFAX, Nova Scotia, May 12, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the achievement of another milestone in its regulatory strategy by receiving the CE mark for its Multiplo ® Complete Syphilis (TP/nTP) Antibody Test (Multiplo ® TP/nT...

MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended January 31, 2022. Profit and Loss Highlights Revenue: The Company recorded revenues in Q2 FY2022 of $297,485 compared to $202,161 in Q1 FY2022 and compared to $347,443 for the...